{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:43:16Z","timestamp":1761709396411,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.purol.2017.07.242","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T22:16:39Z","timestamp":1504131399000},"page":"609-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Place de la t\u00e9mocilline dans le traitement des infections urinaires"],"prefix":"10.1016","volume":"27","author":[{"given":"M.","family":"Vall\u00e9e","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Roblot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.purol.2017.07.242_bib0225","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jac\/dks429","article-title":"10-Fold increase (2006\u201311) in the rate of healthy subjects with extended-spectrum (-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre)","volume":"68","author":"Nicolas-Chanoine","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.purol.2017.07.242_bib0230","unstructured":"R\u00e9sistance aux anti-infectieux\/Maladies infectieuses\/Dossiers th\u00e9matiques\/Accueil [Internet]. [cit\u00e9 7\u00a0f\u00e9vr 2017]. Disponible sur\u00a0: http:\/\/invs.santepubliquefrance.fr\/Dossiers-thematiques\/Maladies-infectieuses\/Resistance-aux-anti-infectieux."},{"issue":"6","key":"10.1016\/j.purol.2017.07.242_bib0240","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/jobm.201700008","article-title":"Extended spectrum \u03b2-lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern","volume":"57","author":"Padmini","year":"2017","journal-title":"J Basic Microbiol"},{"issue":"2","key":"10.1016\/j.purol.2017.07.242_bib0245","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.purol.2017.07.242_bib0250","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.purol.2017.07.242_bib0255","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.purol.2017.07.242_bib0260","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.purol.2017.07.242_bib0265","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/jac\/dkl046","article-title":"In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli","volume":"57","author":"Rodriguez-Villalobos","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.purol.2017.07.242_bib0270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","article-title":"What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline","volume":"37","author":"Livermore","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.purol.2017.07.242_bib0275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/dkq388","article-title":"Trends in production of extended-spectrum \u03b2-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals","volume":"66","author":"Rodriguez-Villalobos","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.purol.2017.07.242_bib0280","first-page":"853","article-title":"Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14\u00a0and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae","volume":"119","author":"Titelman","year":"2011","journal-title":"ResearchGate"},{"issue":"3","key":"10.1016\/j.purol.2017.07.242_bib0285","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s15010-013-0441-z","article-title":"Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea","volume":"41","author":"Kim","year":"2013","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.purol.2017.07.242_bib0290","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.medmal.2013.01.006","article-title":"Alternatives to carbapenems in ESBL-producing Escherichia coli infections","volume":"43","author":"Fournier","year":"2013","journal-title":"Med Mal Infect"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.purol.2017.07.242_bib0295","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1469-0691.2007.01853.x","article-title":"beta-Lactams without a suicide inhibitor","volume":"14","author":"Giamarellou","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.purol.2017.07.242_bib0300","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1128\/JCM.01692-14","article-title":"Evaluation of carbapenemase screening and confirmation tests with Enterobacteriaceae and development of a practical diagnostic algorithm","volume":"53","author":"Maurer","year":"2015","journal-title":"J Clin Microbiol"},{"issue":"2\u20134","key":"10.1016\/j.purol.2017.07.242_bib0305","first-page":"144","article-title":"In vitro Temocillin efficacy against extended spectrum \u03b2-lactamase producing multidrug resistant Gram negative bacterial isolates from Nepal","volume":"16","author":"Kandel","year":"2014","journal-title":"Nepal Med Coll J"},{"issue":"2","key":"10.1016\/j.purol.2017.07.242_bib0310","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/23744235.2015.1087648","article-title":"The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010\u20132011","volume":"48","author":"Zykov","year":"2016","journal-title":"Infect Dis (Lond)"},{"issue":"5","key":"10.1016\/j.purol.2017.07.242_bib0315","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dku542","article-title":"Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15","volume":"70","author":"Soubirou","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.purol.2017.07.242_bib0320","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3346\/jkms.2014.29.8.1178","article-title":"Susceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea","volume":"29","author":"Seo","year":"2014","journal-title":"J Korean Med Sci"},{"year":"2015","series-title":"Infections urinaires communautaires de l\u2019adulte: actualisation: place du trim\u00e9thoprime et de la t\u00e9mocilline","author":"SPILF","key":"10.1016\/j.purol.2017.07.242_bib0325"},{"issue":"1","key":"10.1016\/j.purol.2017.07.242_bib0330","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/dkm179","article-title":"Temocillin susceptibility by BSAC methodology","volume":"60","author":"Andrews","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.purol.2017.07.242_bib0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF02148656","article-title":"Interpretive criteria for temocillin disk diffusion susceptibility testing","volume":"4","author":"Fuchs","year":"1985","journal-title":"Eur J Clin Microbiol"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.purol.2017.07.242_bib0340","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003495-198500295-00050","article-title":"Influence of temocillin on colonisation resistance and consequences for therapy","volume":"29","author":"De Vries-Hospers","year":"1985","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.purol.2017.07.242_bib0345","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/14656566.2014.914172","article-title":"Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches","volume":"15","author":"Karaiskos","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.purol.2017.07.242_bib0350","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.purol.2017.07.242_bib0355","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003495-198500295-00023","article-title":"Effect of renal function and dialysis on temocillin pharmacokinetics","volume":"29","author":"Boelaert","year":"1985","journal-title":"Drugs"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.purol.2017.07.242_bib0360","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003495-198500295-00028","article-title":"Temocillin pharmacokinetics in normal and impaired renal function","volume":"29","author":"H\u00f6ffler","year":"1985","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.purol.2017.07.242_bib0365","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s10096-015-2406-x","article-title":"Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia: results from a retrospective audit","volume":"34","author":"Habayeb","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"year":"2016","series-title":"EAU guidelines on urological infections","author":"Pickard","key":"10.1016\/j.purol.2017.07.242_bib0370"},{"issue":"1","key":"10.1016\/j.purol.2017.07.242_bib0375","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/sur.2013.9999","article-title":"Clinical practice guidelines for antimicrobial prophylaxis in surgery","volume":"14","author":"Bratzler","year":"2013","journal-title":"Surg Infect"},{"year":"2015","series-title":"Comission de transparence de la Haute Autorit\u00e9 de sant\u00e9","author":"HAS","key":"10.1016\/j.purol.2017.07.242_bib0380"},{"issue":"1","key":"10.1016\/j.purol.2017.07.242_bib0385","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.20.1.38","article-title":"BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans","volume":"20","author":"Slocombe","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.purol.2017.07.242_bib0390","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003495-198500295-00021","article-title":"Temocillin. Summary of safety studies","volume":"29","author":"Cockburn","year":"1985","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.purol.2017.07.242_bib0395","first-page":"181","article-title":"Pharmacokinetics of temocillin after intravenous and intramuscular administration","volume":"9","author":"Modr","year":"1986","journal-title":"Czech Med"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.purol.2017.07.242_bib0400","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003495-198500295-00027","article-title":"Renal clearance of temocillin in volunteers","volume":"29","author":"Overbosch","year":"1985","journal-title":"Drugs."},{"key":"10.1016\/j.purol.2017.07.242_bib0405","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit [Internet]. [cit\u00e9 12\u00a0juin 2017]. Disponible sur\u00a0: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0251545.htm."},{"key":"10.1016\/j.purol.2017.07.242_bib0410","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1439-0272.2003.tb00868.x","article-title":"Antibiotic therapy: rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue","volume":"35","author":"Naber","year":"2003","journal-title":"Andrologia"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.purol.2017.07.242_bib0415","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003495-198500295-00034","article-title":"Temocillin concentrations in human tissues","volume":"29","author":"Gould","year":"1985","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.purol.2017.07.242_bib0420","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/17843286.1989.11718041","article-title":"Penetration of temocillin into prostatic tissue after intravenous dosing","volume":"44","author":"Baert","year":"1989","journal-title":"Acta Clin Belg"},{"issue":"11","key":"10.1016\/j.purol.2017.07.242_bib0425","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.purol.2017.07.242_bib0430","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003495-198500295-00037","article-title":"Clinical evaluation of temocillin in urinary tract infections","volume":"29","author":"Asbach","year":"1985","journal-title":"Drugs"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.purol.2017.07.242_bib0435","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00003495-198500295-00048","article-title":"Temocillin treatment of serious infections due to gram-negative bacilli in an intensive care unit","volume":"29","author":"Offenstadt","year":"1985","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.purol.2017.07.242_bib0220","first-page":"171","article-title":"Temocillin in the treatment of pyelonephritis in children","volume":"13","author":"Verboven","year":"1987","journal-title":"Drugs Exp Clin Res"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708717304104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708717304104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:29:32Z","timestamp":1761114572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708717304104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1166708717304104"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2017.07.242","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Place de la t\u00e9mocilline dans le traitement des infections urinaires","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2017.07.242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}